The tremendous success of Intuitive Surgical over the past two decades seems clearly to argue that robotics is more than a techy's pipedream. Intuitive has already revolutionized at least one procedure - laparoscopic prostatectomy - and it figures to make significant progress in a range of others, in men's health, women's health, and cardiovascular surgery, to name just a few relevant clinical spaces. Even more impressive has been its success as a publicly traded company; for much of the middle years of this decade, Intuitive's stock was the strongest performer among all medical device public offerings. And perhaps most interesting: until recently, Intuitive was virtually the only robotics company to achieve any kind of success at all. In Vivo interviews Lonnie Smith, the CEO of the company for much of the 1990s and 2000s, to whom much of the credit should go.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
